In mouse models of Crohn's disease, BPC-157 administration led to significant decreases in the size of intestinal lesions
Whether they reflect dose-related issues, sourcing variability, or true pharmacological effects is unknown, precisely because the human data does not exist to answer that question
While you may be tempted to use a vial that is a few days past its expiration, the risk is simply not worth it
In published research literature after 2010, AOD-9604 began to appear in combination protocols , as a secondary molecule added to GH combinations, GLP-1 agonists or regenerative peptides
The Process was very quick and easy
Contraindications: Hypersensitivity to Hydroxocobalamin or to any of the excipients